Diabetic kidney disease (DKD) is the leading cause of end stage renal disease in adults. In DKD the increased activation of renin-angiotensinaldosterone system (RAAS) via the elevated angiotensin II and aldosterone contributes to renal fibrosis. Although RAAS inhibitors are the gold standard therapy in DKD, their antifibrotic effect has not been tested yet. Different growth factors (TGFb, PDGF, CTGF) have a key role in the development of fibrosis by regulating mesenchimal cells, but their signal-transduction pathway in DKD is still not clarified. METHODS: Human kidney 2 (HK2) proximal tubular cells were cultured in normal (5.5 mM) and high glucose (35 mM) medium and treated with RAAS inhibitors. Untreated or isosmotic mannitol (35mM) cultured cells were used as controls. Renal fibroblasts were treated with PDGF (10 ng/mL) and RAAS inhibitors. Cell proliferation, expression of TGFb, PDGF, CTGF and aSMA levels were measured.After five weeks of streptozocin (65 mg/bwkg, i.p.) induced diabetes male, adult Wistar rats were treated for two weeks p.o. with enalapril, ramipril, losartan, spironolactone or eplerenone (40-10-20-50-50 mg/bwkg/day, resp.). Vehicle-treated diabetic (D) and healthy animals were controls (n¼6/group). Blood pressure, renal and metabolic parameters were measured. Tubulo-interstitial fibrosis, fibronectin and collagen levels were evaluated. Fibrotic marker levels were also measured from the kidney. RESULTS: High glucose increases PDGF and TGFb production of HK2 cells, that in turn induces proliferation and aSMA production in fibroblasts. These changes are likely to be due to the presence of hyperglycemia than to glucose induced hyperosmolarity.In diabetic rats the declined renal function and tubulointerstitial damage was ameliorated by RAAS blockers. The interstitial fibrosis, the amount of fibronectin and collagen were decreased by all RAAS inhibitors. Elevated renal PDGF, aSMA, CTGF, MMP2 and TIMP1 levels were decreased by RAAS blockers. Aldosterone antagonists showed the most robust effect in improving GFR (D: 1.360.1 mL/min/100g vs LOS: 1.960.1 mL/min/100g, EPL: 1.960.1 mL/min/100g, p<0.05 resp.), decreasing fibronectin accumulation (1.5 -2.1 fold decrease in LOS and EPL vs D resp.) as well as minimizing PDGF and CTGF production (D vs LOS and EPL, p<0.05 resp.). CONCLUSIONS: In proximal tubular cells hyperglycemia-induced growth factor production increases the proliferation and transformation of renal fibroblast, contributing to the development of fibrosis. RAAS blockers, directly acting on fibroblasts, decrease the production of profibrotic factors, by this ameliorate the process of renal fibrosis. All these findings suggest a new therapeutic potential of RAAS blockers, preferentially
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The hormone resistin appear to have a relevant role on several pathological pathways in complex illness such as diabetes, cardiovascular disease, liver disease, chronic kidney disease, auto-immune disease and several inflammatory conditions. More than that, high serum resistin levels have been associated with increased risk of cardiovascular disease in the general population. Diabetic and renal impaired patients seems to present with the biggest risk.The aim of this study is to determine the role of serum resistin levels as a predictor of hospital admissions triggered by cardiovascular episodes in type 2 diabetic patients with mild to moderate CKD. METHODS: An observational study enrolled 78 diabetic patients with mild to moderate CKD which were screened and selected in an outpatient diabetic nephropathy clinic and were followed from January 2008 to December 2016. RESULTS: Out of the total 78 patients included, 13 were admitted at the hospital and newly diagnosed with cardiovascular pathology. There was a statistically significant result for resistin as a predictor of cardiovascular related hospital admissions (p < 0.05). Laboratory parameters such as creatinine clearance, albumin, HbA1c, phosphorous, PTH, insulin resistance, CRP, resistin and active vitamin D, were positively related to cardiovascular hospital admissions. CONCLUSIONS: Serum resistin levels demonstrated to be a valuable instrument to predict cardiovascular hospital admissions in type 2 diabetic patients with mild to moderate CKD. Also, other factors often altered in type 2 diabetics and patients with renal impairment were associated with hospital admissions but didn't prove to have any potential in predicting hospital admissions in this group. Most current insulin therapies involve subcutaneous injections, or use of infusion devices which are inconvenient and repeated injections, result in localized insulin deposits that lead to local hypertrophy and fat deposits under the skin. Therefore, our study have been focused on self-regulatory insulin release systems that can carry out feedback control of insulin delivery, based on blood glucose levels, or to develop systems like "artificial pancreas".Hence, it was envisaged to develop glucose responsive serum stable and long circulating liposomes as drug delivery system .The inclusion of PEG derivatized lipids stabilized liposomes in circulation and enhanced encapsulation efficiencies. It also reduced leakage of drug from liposomes, which might contribute to the sustained release of encapsulated insulin. METHODS: Liposomes were prepared by cast film method and and pegylated. Pegylated liposomes were characterized for vesicles shape, entrapment efficiency, vesicles size analysis, pH dependent aggregation, glucose induced aggregation and invitro drug release.
RESULTS:
The Photomicrograph and TEM studies show spherical shape. The in-vitro studies included glucose permeation study and glucose induced aggregation study. Invivo studies were done on both diabetic and non-diabetic rats and included blood glucose determination. The hypoglycemic effect by PEG-coated liposomes lasted for much longer duration than uncoated liposomes. The slow release of insulin from coated liposomes achieved longer duration of hypoglycemic activity. The difference between glucose responsive and non-glucose responsive systems is more evident in normal rats than diabetic rats. CONCLUSIONS: The PEGylated glucose responsive system confers the longer circulating properties and senses the elevated blood glucose levels and release insulin in higher proportions when compared to Non-PEGylated system. 
